Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Aldeyra Therapeutics Inc
ALDX | US
5.53
USD-0.17
-2.98%
ALDX | US
About Aldeyra Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
5.53
Open
5.63
High
5.70
Low
5.48
Aldeyra Therapeutics Inc. a biotechnology company develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap a reactive aldehyde species (RASP)modulator which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629 an orally administered RASP modulator for treatment of COVID-19 atopic asthma psoriasis and alcohol intoxication; and ADX-2191 a dihydrofolate reductase inhibitor for the treatment primary vitreoretinal lymphoma cancer proliferative vitreoretinopathy and retinitis pigmentosa as well as rare retinal diseases characterized by inflammation and vision loss. In addition it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics Inc. and changed its name to Aldeyra Therapeutics Inc. in March 2014. Aldeyra Therapeutics Inc. was incorporated in 2004 and is based in Lexington Massachusetts.
View LessALDX | US
Risk
36.8
Sharpe
1.96
Luna's Score
57/100
Recommendation
Hold
Luna says (ALDX | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Sharpe Ratio (> 1.2)
What's not Working
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
31.4%1 month
36.8%3 months
92.6%6 months
77.4%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
3.35
Debt to equity
0.16
Debt to assets
0.12
Ent. to EBITDA
-3.50
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-42.80M
MarketCap
328.60M
MarketCap(USD)
328.60M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-33.19
Short ratio
5.57
Short perc.
6.08
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.79
Range1M
0.87
Range3M
3.41
Volumes: Market Activity
Rel. volume
0.95
Price X volume
2.26M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.50 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.35 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 92.57 | - | Riskier |
| Debt to Equity | 0.16 | -1.23 | Expensive |
| Debt to Assets | 0.12 | 0.25 | Cheaper |
| Market Cap | 328.60M | - | Emerging |
